GlassScriptPhysician profile
Ming Chi Hsiao
NPI 1588096127
$45,728.13
in general payments reported to CMS, 2019-2025
23 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $856 · 2023: $15K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $10K · Food and Beverage: $7,210 · Consulting Fee: $2,050 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,968.00 |
| Travel and Lodging | $10,190.75 |
| Food and Beverage | $7,210.10 |
| Consulting Fee | $2,050.00 |
| Education | $172.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $42,043.62 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $1,046.96 | 2021-2025 | Remodulin, Tyvaso, Orenitram |
| Merck Sharp & Dohme LLC | $545.52 | 2021-2025 | Winrevair, Verquvo |
| E.R. Squibb & Sons, L.L.C. | $353.81 | 2021-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $250.47 | 2022-2024 | Farxiga |
| Kestra Medical Technology Services, INC. | $240.18 | 2024-2025 | Assure Wcd |
| Amgen INC. | $206.15 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.93 | 2023-2025 | Lifevest |
| Abbott Laboratories | $175.90 | 2021-2025 | Cardiomems |
| Abiomed | $145.95 | 2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $97.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $93.04 | 2023-2024 | |
| Pfizer INC. | $70.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.27 | 2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $34.45 | 2021-2024 | Onpattro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $31.05 | 2024 | Barostim Neo System |
| Daiichi Sankyo INC. | $24.62 | 2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $23.00 | 2024 | |
| Shield Therapeutics INC | $22.76 | 2024 | |
| Scpharmaceuticals INC. | $19.99 | 2023 | |
| Boston Scientific Corporation | $18.35 | 2023 | Watchman |
| Medtronic, INC. | $17.99 | 2025 | Invos |
| Janssen Pharmaceuticals, INC | $14.36 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Chi Hsiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.